Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Check market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 9,265,893

« Back to Dashboard
Patent 9,265,893 protects LEVEMIR FLEXPEN, VICTOZA, NOVOLOG MIX 70/30 FLEXPEN, and NOVOLOG FLEXPEN, and is included in four NDAs. There has been one Paragraph IV challenge on Victoza.

This patent has thirteen patent family members in twelve countries.

Summary for Patent: 9,265,893

Title:Injection button
Abstract: A push button connection for an injection device comprising a push button (10) and a driving part (20). The two parts of the push button connection are mounted to each other and is relatively rotatable to each other. In order to minimize the friction occurring between the push button and the driving part when relatively rotated forces are transmitted via a pivot bearing (18, 22). In order also to minimize the effect of forces appearing dislocated from the center line a number of radial bearings (13, 23; 14, 25) having a little friction diameter is provided.
Inventor(s): Hansen; Torben Stroem (Copenhagen V, DK), Wielandt; Jakob Oest (Copenhagen N, DK), Groth; Lars Moerch (Fredensborg, DK)
Assignee: Novo Nordisk A/S (Bagsvaerd, DK)
Application Number:12/525,976
Patent Claim Types:
see list of patent claims
Patent Metrics:
Source: PatentQuant.com
Field: Not categorized
Back Citations: 183rd percentile
Forward Citations: 0th percentile

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Novo Nordisk Inc
insulin detemir recombinant
INJECTABLE;SUBCUTANEOUS021536-002Jun 16, 2005DISCNNo9,265,893► subscribeY
Novo Nordisk Inc
liraglutide recombinant
SOLUTION;SUBCUTANEOUS022341-001Jan 25, 2010RXYes9,265,893► subscribeY
Novo Nordisk Inc
insulin aspart protamine recombinant; insulin aspart recombinant
INJECTABLE;SUBCUTANEOUS021172-004May 3, 2002RXYes9,265,893► subscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 9,265,893

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
07101729Feb 5, 2007
PCT Information
PCT FiledJanuary 21, 2008PCT Application Number:PCT/EP2008/050624
PCT Publication Date:August 14, 2008PCT Publication Number: WO2008/095762

International Patent Family for Patent: 9,265,893

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Japan2010517650► subscribe
Spain2351778► subscribe
European Patent Office2109474► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.